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Measurement of Mutational Flow Implies Both a High New-Mutation Rate
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We describe a new approach for analysis of the epidemiology of progressive genetic disorders that quantifies the
rate of progression of the disease in the population by measuring the mutational flow. The framework is applied
to Huntington disease (HD), a dominant neurological disorder caused by the expansion of a CAG-trinucleotide
sequence to 135 repeats. The disease is 100% penetrant in individuals with 42 repeats. Measurement of the flow
from disease alleles provides a minimum estimate of the flow in the whole population and implies that the new
mutation rate for HD in each generation is 10% of currently known cases (95% confidence limits 6%–14%).
Analysis of the pattern of flow demonstrates systematic underascertainment for repeat lengths !44. Ascertainment
falls to !50% for individuals with 40 repeats and to !5% for individuals with 36–38 repeats. Clinicians should
not assume that HD is rare outside known pedigrees or that most cases have onset at age !50 years.
Introduction
Huntington disease (HD [MIM 143100]) arises gradu-
ally. Subtle motor disorders (Smith et al. 2000) and cog-
nitive deficits (Lawrence et al. 1998) precede chorea,
psychiatric disturbances, and global cognitive deterio-
ration. According to Harper (1992, p. 366), “in HD,
more than most genetic disorders, all investigators are
struck by the number of new affected patients discovered
through a detailed and systematic family survey, often
as a result of a home visit, whose existence was totally
unsuspected, and who would not have been included in
any survey limited to primary cases.”
HD shows anticipation, with onset tending to become
earlier in successive generations. The disease is caused by
the expansion of a CAG repeat in the HD gene (The
Huntington’s Disease Collaborative Research Group
1993). In European populations, most alleles at the locus
have 15–20 repeats. The disease affects individuals with
an allele with 36 repeats, but for chromosomes with
!41 repeats it is variably penetrant within the normal
human life span (Rubinsztein et al. 1996; McNeil et al.
1997). Median age at onset becomes progressively earlier
as repeat length increases (Brinkman et al. 1997). Alleles
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with 36 repeats are highly mutable. The mutation rate
is higher in the male germ line, where most of the changes
involve increases in repeat length (i.e., there is an upward
bias [Kremer et al. 1995; Leeflang et al. 1995]), providing
a molecular basis for anticipation.
Before the genotype responsible for HD was deter-
mined, new mutations were generally believed to be
very rare (Conneally 1984; Harper 1992). Because of
the frequent late onset of the disease and the possibility
of false paternity, it was difficult to confirm that any
individual case was a bona fide newmutation, andmany
researchers assumed that ambiguous cases were unlikely
to be genuine (e.g., see Shaw and Caro 1982). The iden-
tification of the HD gene revealed unambiguous evi-
dence of a significant level of new mutation. It was
found that, for ∼1%–3% of patients, neither parent had
a CAG repeat of size36 (Andrew et al. 1997). In each
of these cases, the new mutation had arisen on paternal
transmission of an allele with 27–35 repeats (Goldberg
et al. 1993). These repeat lengths, which are rare in the
normal population, have been designated “intermediate
alleles.” They give no risk of disease to the individual
but do give a small risk to his or her children.
Alleles with 36–39 repeats are rare among recognized
disease chromosomes (e.g., see Kremer et al. 1994). This
rarity, in all likelihood, reflects underascertainment due
to incomplete penetrance and/or late onset of the dis-
ease. Because of this underascertainment, it seems to
follow that we cannot be measuring all the mutations
occurring in the population that increase repeat length
to 36. Here we consider the evolution of the disease
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genotype within a population context. We show that a
more meaningful estimate of the new mutation rate can
be achieved through measurement of the mutational
flow. The flow reflects the progression of the genotype
within the population in each generation, which, in
turn, determines the rate at which new families with
HD arise. By comparing the pattern of flow observed
for disease alleles with the pattern expected in the whole
population, we are able to estimate the degree of un-
derascertainment of each CAG length.
Material and Methods
HD Chromosomes
We used CAG measurements from the HD pedigree
collection of the Centre for Molecular Medicine and
Therapeutics (CMMT) at the University of British Co-
lumbia in Vancouver. The cohort is composed of indi-
viduals of primarily Canadian origin, although people
of South African and northern-European descent are
also represented. The database contained 1,830 geno-
typed individuals with 36 repeats. The database was
also searched for parent-to-offspring transmissions of
disease chromosomes, defined as length 36 in either
parent or offspring; a total of 459 were found.
During the history of the database, CAG length has
been measured by three different methods, the earliest
of which included the flanking CCG repeat. For the pres-
ent study, it was important to maximize the number of
available transmissions, while avoiding bias that might
result from parent and offspring CAG length being mea-
sured by a different method. For measurement of CAG
length in each transmission, we therefore chose the most
accurate method for which both parent and offspring
data was available. Eight transmissions were excluded
because there were no matching measurements; this left
a total of 451. The flanking CCG was included for 328
of the disease-chromosome measurements and for 143
of the transmissions. Excluding these data increases the
sampling variance but does not significantly change any
estimate (data not shown).
Mutational Model
Amutational model can be used to describe the repeat-
length change, either from parents to offspring, or during
the mitotic divisions in the germ cells of a single indi-
vidual, or over time in a population. Here we use var-
iations of the same model, for all three purposes.
The CAG repeat can mutate to either a longer or a
shorter length. The simplest model (the stepwise-muta-
tion model of Kimura and Ohta [1978]) assumes that
there is an equal probability of increases and decreases
and that the mutation rate is independent of the length
of the repeat. Neither of these assumptions is applicable
at the HD locus. Large alleles have higher mutation
rates, and there is also evidence of an upward bias. Fol-
lowing Rubinsztein et al. (1994), we define a model that
can incorporate these characteristics.
Under the model, mutation acts by changing the fre-
quency p(x,t) of repeats that are length x at time t. The
mutation rate is given by mxn, where m is a constant and
n determines the degree of length dependence of the mu-
tation rate. For , the mutation rate is independentn p 0
of repeat length, whereas for the mutation raten 1 0
increases progressively for larger repeat lengths. We as-
sume that all repeat-length changes are either stepwise
additions or stepwise subtractions of a single repeat:
of the changes are stepwise increases of one(1 b)/2
repeat, and the other are stepwise decreases;(1 b)/2
b determines the mutation bias and is constrained to lie
between 1 (all mutations decrease repeat length) and
1 (all mutations increase repeat length).
The model has an upper boundary b. All repeats that
reach the boundaries are removed. The total frequency
of repeats must stay equal to 1, at all times. This is
achieved by use of a renormalizing term z(t). The rate
of change of p(x,t) is given by
dp(x,t) 1 b n{ p(x 1,t)m (x 1)
dt 2
1 b np(x 1,t)m (x 1)
2
np(x,t)mx  z(t)p(x,t) , (1)
for values of , with . The renormalizingx ! b p(b,t) { 0
term is
1 b nz(t) { m (b 1) p(b 1,t) .
2
The upper boundary is necessary to make the model well
defined and capable of being simulated, since, in its ab-
sence, repeat length will run off to infinity when b 1 0
and (Falush and Iwasa 1999). We use the boundaryn 1 2
to represent selection against very large repeats—for ex-
ample, those due to early onset of HD. For these pa-
rameter values, increasing the value of b has little effect
on the distribution of shorter repeats (D.F., unpublished
data). The reason is that, once arrays have reached a
large length, they increase very rapidly with high prob-
ability and will quickly hit the boundary wherever it is
located. For this reason, the main criterion that should
be used in choosing b when fitting the model to empirical
data is that it should include the largest observed repeat
length.
The continuous-time definition of the model (eq. [1])
differs from that of Rubinsztein et al. (1994), who as-
sumed discrete time intervals. Our definition has the
advantage that the same model can be adapted to dif-
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ferent contexts by measuring time in different units. In
order to simulate sperm repeat-length distributions, time
is assumed to be proportional to the number of mitoses.
According to established physiological models, the num-
ber of mitoses undergone by a sperm of a man of age a
is approximately , whereas eggs un-34 23(a 13)
dergo 24 mitoses, irrespective of age (Vogel and Rath-
enberg 1975). In order to simulate populations, on the
other hand, time is assumed to be proportional to the
number of generations. In the generational model, we
do not distinguish between males and females. To con-
vert between mitotic and generational models, we use
194 as the average number of mitoses. We obtain this
number from the consideration that the mean age of
fathers in the database is 28.13 years, implying an age
of ∼27.4 years at the date of conception. On the ba-
sis of the formulas above, there are, on average, 364.8
mitoses in the male germ line and 24 in the female germ
line, or an average of 194 mitoses for the sexes com-
bined.
We simulated one generation of a finite population by
starting with the initial frequency distribution in the pop-
ulation and running equation (1) for one generation.
This provided the frequency distribution expected in the
next generation. To calculate the actual numbers for
each repeat length, random numbers were generated
from a multinomial distribution. To record the muta-
tional flow in the final generation of the simulation, we
separately calculated, for each combination of x and y,
the expected and actual numbers that mutated from
length x to length y. This method of simulation (which
also differs from that of Rubinsztein et al. [1994]) has
the advantage that the simulation time is almost inde-
pendent of population size, making it practical to sim-
ulate very large populations.
Results
Mutational Properties of Disease Alleles
Leeflang et al. (1999) measured the CAG length of
3,672 sperm carrying an HD disease allele, by using
single-sperm PCR. The sperm were collected from 26
individuals in the large Venezuelan pedigree with HD.
The range of somatic repeat length of their disease alleles
was 37–62. To estimate mutational parameters on the
basis of the data, we assumed that the initial distribution
( ) for sample j with somatic repeat length sj wast p 0
p (s ,0) p 1 ;j j
p (x,0) p 0 for all other repeat lengths x .j
We set to include the largest sperm (lengthb p 160
159) in Leeflang et al.’s sample. The model is run for
time , where aj is the age at whicht p 34 23(a  13)j j
the sperm sample was collected. The total log likelihood
that the data will be observed in all samples, given the
mutational parameters m, n, and b, is
l(m,n,b) p m logp (i,t ) , ij j j
j i
where mij is the number of sperm in sample j that have
i repeats.
We fitted the mitotic model to the distribution for all
27 samples (one individual was sampled at two ages),
using a grid search to find the combination of parameters
that gave the highest likelihood. To limit the search time,
we considered only integer values of n. We obtained
estimates for the mutation bias, ; the degree ofb p .277
length dependence of the mutation rate, ; and then p 8
mutation rate per mitosis, . These pa-15m p 1.05# 10
rameters imply that, for a repeat of length 40, the mu-
tation rate per mitosis is 0.0069. The model (represented
by the line in each graph in fig. 1) accurately predicts
both the modest skew observed in the sperm of individ-
uals with somatic repeat lengths !44 (e.g., sample S
shown in figure 1) and the more-pronounced skew in
individuals with repeat lengths 44–49 (e.g., sample N).
The mitotic model fits the data significantly better than
does a model that incorporates no age dependence
(dashed line in fig. 2; , by likelihood-ratio test)P K .01
but, nevertheless, fails to explain a large proportion of
the interindividual variation in mutational spectra. In
particular, for sample P the sperm repeat length has a
much higher mean and variance than are predicted by
the model, and for sample A it has a much higher mean.
The deviation from the model shows little obvious pat-
tern, except that the model tends to underestimate the
upward bias for somatic repeat lengths 149. Most of the
remaining variation is not attributable to either age or
CAG length.
We have also tested the model by using pedigree data,
by comparing the distribution of sizes of mutations ob-
served in transmissions of disease chromosomes versus
the prediction by the model when the parents’ repeat
length, age, and sex are given (fig. 3). The sample is not
a random subset of all such transmissions, however, since
the phenotype of the offspring has played some role in
the ascertainment of approximately half of the sample
(table 1). As a consequence, we expect to observe more
increases in repeat length—and fewer decreases—than
the model predicts. For this reason, it is not appropriate
either to estimate model parameters on the basis of ped-
igree data or to assess the fit of the model quantitatively.
The model fits the observed pattern of paternally derived
mutations quite well, although it underestimates the
number of large increases. With regard to maternal
transmission, the model significantly underestimates
both the number of large increases and the number of
large decreases. This concords with evidence from other
microsatellite loci (Huttley et al. 2000), which implies
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Figure 1 Repeat-length distribution for 8 of the 27 samples collected by Leeflang et al. (1999), compared with the distributions predicted
by the mitotic model. The samples were chosen to illustrate the full range of variation—both in terms of mutational properties and in terms
of goodness of model fit—that was observed in the data.
that the sex difference in mutation rate is smaller than
would be predicted on the basis of the relative number
of mitoses in male versus female germ lines.
We can also test the fit of the generational model to
the pedigree data. We assume 194 mitoses per genera-
tion, as estimated, above, on the basis of the average
number of mitoses in the male and female germ lines.
A mutation rate of 0.0069 per mitosis for a repeat of
length 40 implies an average of 1.34 mutations per gen-
eration. However, after the repeat has mutated once, the
mutation rate changes. Although, since it does not dis-
tinguish between maternal and paternal transmission,
this model may appear oversimplified, it gives a reason-
able fit to the distribution of mutation sizes observed in
all 451 transmissions (fig. 3C). The frequency of large
increases is again underestimated.
In summary, we have shown that a simple length-
dependent mitotic model can account adequately for (a)
the repeat-length distribution observed in individual
sperm samples, (b) the mutation-rate variation between
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Figure 2 Mean (A) and variance (B) of repeat-length distribution in 27 sperm-typing samples collected by Leeflang et al. (1999) (dots),
compared with the corresponding values as predicted by the mitotic model (crosses). The dashed line indicates the values expected under the
best-fit model with no age effect. The solid line in panel A shows the length that would be observed if all sperm were identical to somatic cells.
The fact that all points are above this line shows that there is an upward bias in the germ line of each individual. The somatic repeat lengths
of some samples have been displaced fractionally from integer values, to maximize their visibility on the graphs. The letters indicate the sample
names used by Leeflang et al.
samples with different somatic repeat lengths, and (c)
the overall pattern of mutation observed in disease-chro-
mosome transmissions. Mutation is upwardly biased for
all repeat lengths, and the mutation rate is strongly de-
pendent on the length of the repeat. Under the best-fit
model, there are 1.77 stepwise increases in length for
every stepwise decrease, and the mutation rate per mi-
tosis is 60 times higher for repeats of length 60 than for
repeats of length 36.
Although the model accounts for most features of the
empirical data, there are some discrepancies:
1. The model underestimates the mutation rate for
female transmission. Both increases and decreases in
length are more common than expected. This discrep-
ancy arises either because there is an elevated mutation
rate in the meiotic divisions, because there are replica-
tion-independent mutational events, or because of qual-
itative mutation differences between male and female
germ lines. The elevated level of large deletions in the
maternal data suggests a qualitative difference in mu-
tational properties, but further data are needed to con-
firm this. At other (i.e., nontrinucleotide) disease loci,
there is evidence for an elevated level of deletions in the
female germ line (Grimm et al. 1994).
2. In the Leeflang et al. data set, there is substantial
interindividual variation that cannot be accounted for
by either age or somatic repeat length. These individuals
share the same haplotype, so the variation is not due to
genetic variation at closely linked sites (i.e., to cis-acting
factors); instead, it must be attributed to either stochastic
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Figure 3 Expected distribution of changes (% of sample), in one
generation, under the mitotic model, comparedwith observations from
209 paternal transmissions (A), 214 maternal transmissions (B), and
the complete sample of 451 transmissions (C).
Table 1
Disease-Chromosome Transmissions in the CMMT Database
PARENTAL SOURCE OF TRANSMISSION
AND STATUS OF OFFSPRING
NO. OF CASES
Parent
Affected
Parent
Unaffected
Paternal:
Affected 88 8
Unaffected:
CAG 36 93 17
CAG !36 68 16
DNA unavailablea 171 8
Maternal:
Affected 90 0
Unaffected:
CAG 36 123 8
CAG !36 121 7
DNA unavailablea 244 3
Sex of parent unknown:
Affected 9 0
Unaffected:
CAG 36 12 2
CAG !36 7 1
DNA unavailablea 13 1
NOTE.—In this table, we show all cases in which the parent
has a chromosome with CAG 36, as well as those in which
the parental chromosome has given rise to a new mutation in
one of his or her children. When the offspring has CAG !36,
this generally represents a case of nontransmisssion of the disease
chromosome.
a Offspring has been entered into the database but, as yet, has
not requested genetic testing through the CMMT.
mutational events in early germ cell divisions (clustered
mutation [Jones et al. 1999]), genetic variation in germ-
line mutational properties that is caused by unlinked
(trans-acting) factors, or environment. Unfortunately,
none of these factors is easy to investigate or model.
3. Some of the observed large increases and all of the
(very rare) large decreases in repeat length are unlikely
under the model. The pattern of variation that is ob-
served suggests that larger-than-stepwise changes in re-
peat length do occur at a significant rate. However, not
all large changes in length happen because of a single
big event. Each increase in repeat length elevates the
mutation rate, so large increases can occur through re-
peated small mutations in the course of the numerous
male germ-cell divisions, especially in individuals with
elevated mutation rates.
4. The model tends to underestimate the mutational
bias in sperm samples from individuals with somatic
repeat lengths 149.
Likelihood of Observed New Mutations under the
Mitotic Model
New mutations are rare in pedigree data. Of the 451
transmissions in the CMMT database, 8 represent new
mutations to length 36 from a shorter repeat length;
in six of these cases, repeat length had increased by 9
repeats (table 2); the other two transmissions represented
small increases in repeat length that were ascertained on
the basis of affected individuals elsewhere in the
pedigree.
All of the six large increases are very unlikely under
the mutational model (see table 2). The primary reason
for this is the method of ascertainment; new mutations
are detected because of the large repeat length of the
offspring, and they therefore fall within the extreme
right-hand tail of the distribution of repeat lengths in-
herited from intermediate alleles. Even when this ascer-
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Table 2
Genotypic New Mutations in the CMMT Database
REPEAT LENGTH IN
AGE
DIFFERENCE
(years)
OFFSPRING
AFFECTED?
PROBABILITY
OF MUTATIONaFather Offspring
34 36 31 No .21
35 36 36 No .52
31 44 34 Yes 71.7# 10
33 44 27 Yes 62.1# 10
35 45 27 Yes 41.2# 10
30 49 NA Yes NA
34 43 NA Yes NA
27 38 NA Yes NA
NOTE.—Because of the specific interest that the research groups
(e.g., Goldberg et al. 1993, 1995; Chong et al. 1997) have in these
patients, new mutations may be slightly overrepresented in the CMMT
database. To be conservative, we have included only examples inwhich
DNA is available from both parents. In two additional cases, DNA
from only one parent is available; in four other cases, the newmutation
has been inferred on the basis of the repeat length in sibs.
a Under the mitotic model.
tainment effect is taken into account, the large increases
are still not well predicted by the model. The population
frequency of intermediate alleles is ∼1% in European
chromosomes (Goldberg et al. 1995). So we would ex-
pect to observe an event with probability 71.7# 10
(table 2) once, on average, if we sampled from 6#
chromosome transmissions. Although it is difficult810
to quantify, the CMMT chromosomes come from a
much smaller pool of births. The deviations from the
model that are most likely to account for these muta-
tions are either larger-than-stepwise increases or elevat-
ed germ-line mutation rates in a small proportion of
fathers.
Another important issue concerning these new mu-
tations is whether they are representative of the increases
in repeat length to 36 that occur in the population. A
comparison with the repeat-length changes observed in
sperm samples from carriers of intermediate alleles also
suggests that the six large increases are highly atypical.
Of the 95 mutations to length 36 that were observed
by Chong et al. (1997), only 2 were increases of 15
repeats; one of these was an increase of 6 repeats, and
the other was a increase of 8 repeats. From this we
conclude that the majority of ascertained newmutations
are “outliers,” which are detected because they cause an
unusually abrupt change in phenotype. Many new mu-
tations cause mild phenotypes. They are unlikely to be
noticed while the father is still alive, and it is plausible
that they could escape detection for several generations.
A different approach is needed to estimate the true new-
mutation rate for HD.
Estimate of Mutational Flow from Transmissions of
Disease Alleles
The mutational flow is defined as the net number of
chromosomes mutating beyond a given repeat length.
The flow at length 35.5 is the number of chromosomes
mutating from 35 to 36 (the new-mutation rate),
minus the number of chromosomes mutating from 36
to 35 (the back-mutation rate). So, for example, if the
parent has 36 repeats and the offspring has 39, then this
transmission represents a flow of 1 beyond lengths
36.5, 37.5, and 38.5 and a flow of 0 at all other repeat
lengths; if the parent has 37 repeats and the offspring
has 36, then this represents a flow of 1 at length 36.5
and a flow of 0 at all other repeat lengths. The flow is
averaged over all transmissions. The flow is a useful
concept because of its properties in a large population.
Here, we will assume that the human population is large
in the relevant sense.
Figure 4A shows the flow in a simulated large pop-
ulation. There is an approximately constant positive
flow at all repeat lengths between 20.5 and the upper
boundary, which is at length 60. If the flow is measured
at length 45.5, for example, this therefore provides an
estimate of the flow at length 35.5.
The disease-chromosome transmissions that we ob-
serve represent a very small fraction of the transmissions
in the whole population. They are ascertained on the
basis of the disease phenotypes of the parent, child, and/
or other individuals in the pedigree (table 1). In the de-
veloped world, most individuals with a chromosome
with 50 repeats probably come to medical attention,
since disease onset in such cases reliably occurs at age
!40 years (Brinkman et al. 1997). Chromosomes with
length 36–39 are rare among disease chromosomes and
are occasionally found in unaffected individuals from
the general population (e.g., see De Rooij et al. 1993),
so it is clear that ascertainment is lower for these repeat
lengths. What is less clear is the level of ascertainment
between these two extremes. For the moment, we will
assume that ascertainment increases progressively with
repeat length. We will estimate actual ascertainment lev-
els below.
The probability that a transmission in which the par-
ent has x repeats and the offspring has y repeats will be
ascertained depends, in a unknown way, on both x and
y and also on the CAG length in other close relatives.
We consider two very simple models of the ascertain-
ment process. In the first model , ascertainment is entirely
dependent on the CAG length in the parent. The prob-
ability that a particular transmission will be ascertained
is given by d(x), where
d(i) p 0 if i ! 36 ,
i 35
d(i) p if 36  i  45 ,
10{
d(i) p 1 if i 1 45 ;
that is, ascertainment increases linearly from 10%, at
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Figure 4 Mutational flow per 100,000 individuals in a simulated large population. A and B, Flow in a single generation in the whole
population (unbroken line) and as estimated on the basis of disease-chromosome transmission in which ascertainment depends on the repeat
length in either the offspring (dotted line) or parent (dashed line) and increases linearly, from 10% of transmissions, at repeat length 36, to
100% of transmissions, at length 45. A, No selection until repeat length 60. B, 1% Reduction in fitness for each repeat 135. C and D, Flow
(dashed line), estimated differential flow (eq. [2]) (thinner unbroken line), and estimated point flow (eq. [3]) (thicker unbroken line). Both the
estimated differential flow and the estimated point flow are based on the repeat-length distribution and an accurate mutational model. C,Whole
population. D, Ascertained disease chromosomes only. Ascertainment is dependent on repeat length, with ascertainment rates increasing linearly,
from 10%, at length 36, to 100%, at length 45. All results were obtained from a single simulated population of constant size 10,000,000 that
evolved for 10,000 generations after being fixed for 18 repeats. We used the generational model, in which the mutational parameters were
estimated on the basis of sperm-typing data, as explained in the text. The upper boundary value was chosen to optimize visual presentation.b p 60
length 36, to 100%, at length 45. In the second model,
we assume that ascertainment is based on the genotype
of the child, so that the probability that the transmission
will be observed is given by d(y).
Simulation of these models (fig. 4A) shows that, when
ascertainment is based on paternal genotype, flow esti-
mates are negative at some repeat lengths and never ex-
ceed the true flow in the population; in contrast, if flow
estimates are based on offspring genotype, then the es-
timated flow has a peak slightly higher than that of the
true flow. HD normally affects parents first, so that, in
practice (table 1), ascertainment is most dependent on
parental genotype. The model results therefore suggest
that, at all repeat lengths, the ascertained flow should
either equal or underestimate the population flow.
One factor that can alter the pattern of flow is selec-
tion against large alleles, either because of clinical disease
or because of the more subtle, subclinical effects due to
the presence of an expanded CAG repeat. In figure 4A,
there is no selection against disease alleles until they
reach repeat length 60. In figure 4B, by contrast, we
impose progressively stronger selection, starting at
length 36. Fitness is 100% for chromosomes with 35
repeats, 99% at length 36, 98% at length 37, etc. In this
case, the flow decreases beyond length 35.5, so that the
flow at length 45.5 is a substantial underestimate of the
new-mutation rate.
Together, the arguments given above suggest that the
flow will be underestimated for very large repeat lengths,
because of selection against disease alleles, but that it
will also be underestimated for short repeat lengths, be-
cause of incomplete ascertainment. It should therefore
be expected that the flow estimated on the basis of dis-
ease alleles will peak at an intermediate repeat length.
If there is little or no selection before medical ascertain-
ment (as in fig. 4A), then the peak flow will be close to
the net new-mutation rate for the whole population; in
contrast, if there is significant selection, then the new-
mutation rate will be underestimated by the peak flow
(as in fig. 4B).
The flow estimated on the basis of all 451 transmis-
sions of disease chromosomes peaks at length 43.5, at
0.1 per ascertained transmission (fig. 5A). The flowmea-
sured on paternal transmission peaks at 0.20 per trans-
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Figure 5 Mutational flow estimated on the basis of 449 disease-
chromosome transmissions. A, Flow per transmission, in paternal and
maternal inheritance (dashed lines) and in all transmissions (unbroken
line). B, Ratio (flow at length x)/(flow at length 43.5). Bars indicate
95% confidence limits, calculated by means of a percentile bootstrap.
mission, at length 43.5, whereas the maternal flow is
negative at length 40, peaking at 0.05 per transmission,
at length 48. The higher magnitude of flow in paternal
transmission reflects the higher mutation rate and
stronger upward bias. The sex difference in the peak and
trough of the flow reflects a sex difference in the pattern
of ascertainment. For maternal transmissions, the ma-
jority were ascertained on the basis of the phenotype of
the parent alone, whereas, for paternal transmissions,
offspring genotype was more important (table 1). The
simulation results (fig. 4A) correctly imply that, for this
reason, maternal transmission should have both a later
peak and a more negative trough.
The shape of the flow for large repeat lengths provides
evidence on natural selection at the locus. Unfortunately,
the shape has a high sampling variance (fig. 5B). In 2.5%
of bootstrap replicates, the flow at length 53.5 is !40%
of the flow at length 43.5. This would imply strong
selection against alleles of length 44–53. However, in
2.5% of replicates the flow at length 53.5 actually ex-
ceeds the flow at length 43.5, implying little selection
up to length 53 and/or underascertainment of alleles of
length 43.5. Therefore, this sample of mutations offers
inconclusive evidence on the pattern of selection.
The confidence limits of each flow estimate are ap-
proximately inversely proportional to the square root of
the sample size, implying that a fourfold increase in sam-
ple size is necessary to halve the size of the confidence
limit for the flow at a single point. So, if, for example,
we collected 10 times more data, then we might be al-
lowed to conclude that the flow at length 46.5 was
72%–98% of the value at length 43.5, implying signif-
icant selection by length 46, and that the flow is reduced
by between a factor of two and three by length 59.5
(this was calculated by use of our data set repeated 10
times).
Flow Estimation by the Mutational Model
This direct estimate of the flow makes few assump-
tions but has two important limitations. First, the esti-
mated flow at each point is based on a relatively small
number of mutations and, therefore, has a high sampling
variance. Second, ascertainment of the transmissions de-
pends, in a complicated way, on the genotype of parent
and offspring, making it difficult to extrapolate from the
observed level of flow to the degree of underascertain-
ment of shorter disease alleles.
An alternative approach uses the mutational model.
The principle is to use the model to calculate the ex-
pected flow in a single transmission for each disease
chromosome. For simplicity, we ignore both the sex of
the carrier and the question of whether the chromo-
some is in fact transmitted to any offspring. We use the
generational model to calculate the average expected
flow of all of the genotyped disease chromosomes in the
database.
Because our model is defined in continuous time, it is
mathematically natural to calculate the initial expected
rate of flow, rather than the expected flow in a single
transmission. This approach leads to a method for es-
timation of ascertainment levels. On the basis of equa-
tion (1), the expected flow beyond length , perx 0.5
unit of time, is
1 b ndiff(x 0.5) p m x p(x)
2
1 b nm (x 1) p(x 1) , (2)
2
where p(x) is the frequency of chromosomes at length
x. This is the differential flow. When the mutational
model is correct, as in the simulated examples (fig. 4C
and D), the differential flow peaks at approximately the
same level as does the true population flow (fig. 4C).
However, because the statistic is the difference between
two numbers of similar magnitude, it has a high sam-
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Figure 6 Mutational flow estimated on the basis of repeat-length
distribution in 1,830 disease chromosomes. A, Estimated point flow
(unbroken line) and estimated differential flow (dashed line). Because
they have a high sampling variance, repeat lengths 170 are not shown.
B, Ratio (point flow at length x)/(point flow at length 44) (unbroken
line). The ratio provides an estimate of the degree of underascertain-
ment for repeat lengths 144. Bars indicate 95% confidence limits,
calculated by means of a percentile bootstrap.
pling variance. When the differential flow is calculated
on the basis of ascertained disease chromosomes, its
value is very sensitive to ascertainment-level differences
between repeat lengths (fig. 4D), and it gives negative
values at some lengths. It is not possible to estimate
ascertainment levels on the basis of the value of the
differential flow at any one point.
A preferable statistic is the point flow:
1 b 1 b npoint(x) p m p(x) m p(x) p mbx p(x) .
2 2
(3)
The point flow also peaks at approximately the same
level as does the true population flow (fig. 4C), but it
has a lower sampling variance. The value of the point
flow estimated at each repeat length is proportional to
the ascertainment level at that length. This property al-
lows us to make estimates of the degree of underascer-
tainment. The flow peaks at length 44, at 0.093 per
ascertained disease chromosome (fig. 6A). We assume
conservatively that there is 100% ascertainment at
length 44 and that selection has not reduced the fre-
quency of the repeats. The lower value of flow at other
repeat lengths is assumed to be due to both underas-
certainment at shorter repeat lengths and selection
against larger repeat lengths. The value of (point flow
at length x)/(point flow at length 44) then provides an
estimate of the proportion by which selection or under-
ascertainment has reduced the measured flow. This ap-
proach (fig. 6B) implies that incomplete ascertainment
has significantly reduced the measured flow for repeats
of length 42 and that selection has significantly re-
duced it for repeat lengths of 45. Ascertainment levels
drop from 40%, at length 40, to !5%, for repeats of
length 36–38.
Discussion
Mutational Flow and HD Epidemiology
The measurement of mutational flow provides the ap-
propriate framework for analysis of the epidemiology of
dominant disorders caused by a progressive genotype. In
order to measure the flow at a particular point on the
course of a river, the number of molecules crossing the
point that are going upstream is subtracted from the num-
ber that are going downstream. The flow abstracts from
local noise to the totalmovement ofwater. Themutational
flow, defined as the net number mutating past a particular
repeat length, gives a similar insight into the overall pro-
gression of the disease in the population. The flow is cal-
culated by relating the genotype or phenotype (the latter
is not presented) of the parents to that of the offspring.
Flow measurements can be used to estimate the new-mu-
tation rate of the disorder, the level of underascertainment
of mild genotypes or phenotypes, and the strength of se-
lection against severe and mild genotypes.
Our initial application of this approach to HD has
demonstrated that the new-mutation rate for the disease
is much higher than has generally been assumed. HD
has been a textbook example of a genetic disease that,
because its onset typically occurs after reproductive age,
has been at little or no selective disadvantage (e.g., see
Vogel and Molulsky 1986—where, of the genetic dis-
eases listed, HD has the lowest mutation rate). Our anal-
ysis of the pattern of flow demonstrates that this para-
digm is not correct. The peak value of the flow, at length
43.5, implies a historical selective coefficient against dis-
ease chromosomes (as currently ascertained) that is
∼10%.
There are significant practical difficulties involved in
making a rigorous epidemiological estimate of the new-
mutation rate by direct measurement of the mutational
flow. Ideally, parent and offspring CAG length should
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be obtained for all HD births within a given time period
and geographical area. Since CAG testing has become
widespread only recently, and because the age at which
carriers are genotyped varies greatly, it will be many
years before a study can be designed in this way. We
have instead used all available disease-chromosome
transmissions in the CMMT database. These transmis-
sions were mostly ascertained on the basis of parental
phenotype (table 1) and appear to be representative of
the transmissions that result in ascertained disease chro-
mosomes. Simulation results (fig. 4A and B) imply that,
when chromosomes are ascertained on the basis of pa-
rental phenotype, the flow estimates generally will un-
derestimate the true value in the population. Our esti-
mate of 10% is therefore a conservative indication of
the new-mutation rate per disease chromosome per gen-
eration at current ascertainment levels in Canadians and
Europeans. For calculation of the new-mutation rate in
a specific population, our estimate needs to bemultiplied
by the frequency, at birth, of ascertained disease chro-
mosomes; for example, if the offspring of the transmis-
sions in the CMMT database have an ascertainment pro-
file similar to that of known cases of HD in SouthWales,
then a South Wales HD heterozygote frequency of
(Harper et al. 1979) implies a new-mutation42# 10
rate of per birth. Premolecular epidemiological52# 10
estimates (Harper 1992) range between 0 and 0.96#
, with a mode of .5 510 0.08# 10
For an accurate measure of the mutational flow, the
number of transmissions in the sample needs to be very
large. Our estimate of 10%  4% for the peak flow at
length 43.5 is based on 451 disease-chromosome trans-
missions. The sampling variance is high because the flow
represents the difference between two num-
bers of similar magnitude—that is, the number increas-
ing in length minus the number decreasing—and because
only a small fraction of the sample flows beyond any
given point. If a heterozygote frequency of is42# 10
assumed, then these transmissions represent the disease
chromosomes from 2.2 million births. Harper (1992)
has suggested that, for logistical reasons, HD prevalence
estimates should be made for population sizes of
500,000–5,000,000. Several decades of data would be
needed in order to get an equivalent sample size to the
present study, even for populations at the upper end of
this size range. Even our large sample provides only lim-
ited information on selection at the locus. In particular,
the data are consistent with either a sharp peak in the
pattern of flow or a short plateau between lengths 43
and 53: a sharp peak would imply that there is a range
of repeat lengths in which the genotype causes a signif-
icant selective disadvantage but which, nevertheless, is
systematically underascertained; a plateauwould be con-
sistent with the selective neutrality of these genotypes.
Because of the sample-size issue, we have developed
an alternative approach to estimation of the flow, one
that is based on a mutational model of CAG re-
peat–length change. The flow is estimated by calculation
of the expected distribution of CAG repeat-length
changes in a single generation for ascertained disease
chromosomes. The estimates of flow are only as accurate
as the mutational model used to calculate them, but,
depending on the method of calculation, the sampling
variance can be much lower than that based on direct
observation of parent-to-offspring transmissions (com-
pare the sizes of the bars in figs. 5 and 6). In addition,
only one generation of data is needed, which makes co-
hort studies much more feasible. We estimated model
parameters by using Leeflang et al.’s (1999) data from
single-sperm–typing experiments on disease carriers.The
pattern of flow that we obtained from the 1,830 disease
chromosomes in the CMMT database (fig. 6A) is qual-
itatively and quantitatively very similar to that obtained
from disease-chromosome transmissions (fig. 5A) and
implies that selection is progressive and that it probably
overlaps with underascertainment.We also estimated the
minimum degree of underascertainment as a function of
repeat length, using the same approach (fig. 6B).
The mutational flow has important advantages over
traditional measures of disease levels. The peak flow
gives a more accurate indication of the true level of HD
in a population than disease prevalence or incidence be-
cause it is relatively insensitive to ascertainment levels.
Underascertainment chiefly affects more mildly affected
patients, most of whom will have disease alleles shorter
than the repeat length at which the flow peaks. For this
reason, we propose that the comparison of peak flows
should become the method of choice for determining
relative disease levels in different populations. Further-
more, comparison of the pattern of flow could also be
used to measure differences in ascertainment.
Clinical Implications
A rigid distinction between “intermediate alleles,”
which have 29–35 repeats, and “disease alleles,” which
have 36 repeats does not reflect current clinical reality.
Only a small minority of individuals with 36–39 repeats
are medically ascertained. The estimates in figure 6B
imply that, among individuals with 36 CAG repeats,
the number who are never ascertained is twice the num-
ber of those who are ascertained. These estimates are
conservative, because of the possibility of underascer-
tainment at length 44. To include all individuals with
36 CAG repeats, incidence estimates should therefore
be at least tripled. However, a significant proportion of
these individuals do not develop disease (Rubinsztein et
al. 1996, McNeil et al. 1997).
At present, there are no reliable methods for estimat-
ing what proportion of ascertained or unascertained in-
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dividuals with 36 CAG repeats will actually develop
disease. It does not seem feasible to ascertain all indi-
viduals in a population with 36 CAG repeats, and a
prospective cohort study would take several decades.
When retrospective data are used, it is unclear to what
extent ascertainment depends on the phenotype of the
individual, the phenotypes of close relatives, or the al-
ertness of local physicians. Ascertainment based on the
phenotype of the individual would make age-at-onset
distributions calculated on the basis of ascertained in-
dividuals unduly pessimistic—asmight relative-based as-
certainment, if there is heritable variation in suscepti-
bility (McNeil et al. 1997). Random ascertainment due
to local differences in HD awareness would lead to un-
biased estimates. The degree of uncertainty becomes
more acute as ascertainment decreases. Genetic coun-
seling of individuals with 36–39 repeats should mention
both the high degree of uncertainty that surrounds their
prognosis and the good news that they are unlikely to
develop severe clinical symptoms before old age.
We can be sure that many unascertained individuals
do develop disease. For example, our analysis (fig. 6B)
implies that ascertainment levels at lengths 42 and 43
are, respectively, ∼20% and ∼5% lower than those at
length 44. Penetrance is ∼100% at these lengths, be-
cause, of the many individuals who have these repeat
lengths and who have been ascertained on the basis of
affected relatives with larger alleles, very few have been
observed who reach age 60 years and do not develop
the disease. On the basis of this reasoning, it seems very
likely that we are missing 120% of affected individ-
uals with 36–41 repeats. Affected individuals in this
range have a phenotype that, on average, is more mild
than that in individuals with 42 repeats, and they are
also less likely to have affected relatives with larger
expansions.
Late-onset HD principally causes motor disorders and
has a relatively benign course, with little effect on life
expectancy. James et al. (1994) have highlighted the par-
ticular problems concerning the detection and diagnosis
of these motor disorders. In a study of 33 cases with an
onset age of 60 years, they found that only 3 were in-
itially noted by the patient themselves and that more
than half the patients with obvious signs of HD died
either being unaware or continually denying the presence
of symptoms; the 10 individuals in the study who were
genotyped all had either 38 or 39 repeats.
New mutations are much more common than previ-
ously had been thought. Approximately 10% of indi-
viduals who develop clinical disease have parents who,
on the basis of their own phenotype, would not have
been considered to be carriers of HD. Therefore, health-
care workers should not assume that HD is either prin-
cipally a disease of middle age or a disease that is rare
outside known pedigrees. As James et al. (1994) have
stressed, the detection of late-onset cases would make it
possible to inform and council younger generations,who
will often prove to be more seriously affected.
The progress that is currently being made in the un-
derstanding of the pathology of HD gives us a realistic
hope that effective treatments will soon become avail-
able. At that point, it will become important to detect
a higher proportion of the at-risk and mildly affected
individuals in the population. An increased understand-
ing of the ascertainment process will be important in the
development of effective strategies by which this can be
achieved.
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